Please Wait.....
Report
Ulcerative Colitis Market Forecast - Epidemiology & Pipeline Analysis 2022-2027
Market Report I 2022-08-10 I 222 Pages I Arizton Advisory & Intelligence
The ulcerative colitis market is expected to grow at a CAGR of 8.77% during 2022-2027.
Ulcerative colitis is a chronic inflammatory bowel disease (IBD) in which abnormal immune system reactions cause inflammation and ulcers on the inner lining of the large intestine. The ulcerative colitis epidemiology provides insights into the historical and current patient pools and forecasted trends for eight (8MM) major countries. The ulcerative colitis segment covers the historical and forecasted epidemiology data in the US, EU5 (including France, Germany, Italy, Spain, and the UK), China, and Japan from 2021-2027. The Ulcerative colitis epidemiology data are studied through all possible divisions to give a better understanding of the disease scenario in 8MM.
This report provides a detailed analysis of the drugs available for the treatment of ulcerative colitis. The report covers a detailed drug description including drug name, sponsor name, route of administration, molecule type, mechanism of action of the drug, clinical studies, NDA approvals, and Ulcerative colitis (Ulcerative colitis) collaborations, licensing, mergers and acquisition, designations, and other product-related details.
According to Arizton's estimate, the diagnosed incident cases ofinflammatory bowel disease were high in the United States, followed by China and the UK in 2020. The increasing prevalence of ulcerative colitis is driving the growth of the ulcerative colitis drug market. According to the estimates, one million people were affected by inflammatory bowel disease in the US in 2019.
MARKET DRIVERS
Launch of New Therapies: The USFDA approved small molecules such as Jyseleca (Filgotinib) and Rinvoq (Upadacitinib) in 2022 to treat moderate-to-severe ulcerative colitis. The launch of approved small molecules and further uptake in biological therapies will lead to significant growth in the ulcerative colitis therapeutics market.
Increasing Prevalence of Ulcerative Colitis: The market studied has been witnessing considerable growth, which is attributed to the increasing prevalence of inflammatory bowel disease worldwide. According to the estimates, the prevalence of inflammatory bowel disease patients was 910,000 in the United States in 2018.
MARKET TRENDS
High Investment in R&D Activities: Major players in the market are developing products and spending significantly on research and development, along with major acquisitions and collaborations to achieve a competitive edge over their counterparts. High investments in R&D capabilities and infrastructure by the industry and governments are anticipated to create lucrative opportunities in the market.
Presence of Major Players: Companies such as AbbVie, Inc., Pfizer, Inc., Janssen Biotech, Inc. (Johnson & Johnson) are among the major players in the global ulcerative colitis treatment market. These players are focused on adopting organic and inorganic growth strategies to strengthen their product portfolio.
These companies have adopted strategies such as collaborations & acquisitions, expansion of geographical footprint, investments in research & development, and manufacture of novel drugs to compete in the global ulcerative colitis treatment market. The other prominent players operating in the global ulcerative colitis market include Allergan plc, Bausch Health Companies Inc., Takeda Pharmaceutical Company Limited, Novartis AG, Galapogos, and Seres Therapeutics.
Segmentation by Drug Class
- TNF-Alpha inhibitors
- 5-Aminosalicylates
- Corticosteroids & Others
Segmentation by Gender Type
- Men
- Women
Segmentation by Disease Type
- Total Colitis
- Left-sided Colitis & Proctitis
GEOGRAPHY ANALYSIS
The US dominates the ulcerative colitis market due to the rise in healthcare affordability in the US, the rise in knowledge and awareness amongst the people, and the technological advancement in this region. However, the UK is expected to grow at a faster rate with a high CAGR in the ulcerative colitis drug market due to a rise in access and quality of healthcare, an increase in awareness about disease management, and rising healthcare expenditure in this region. The trend of biosimilars in emerging markets, such as China and Japan, could potentially alter the therapeutic landscape in this region.
Drug Class: Among the drug class, TNF-Alpha inhibitors are expected to account for a significant share of the global ulcerative colitis therapeutics market. However, the other class of drugs is expected to be the fastest-growing segment during the forecast period. Recently approved small molecules such as Jyseleca (filgotinib) and Rinvoq (upadacitinib) are expected to drive the global ulcerative colitis therapeutics market during the forecast period.
Gender type: Among the gender type, Men were expected to account for a significant share of the global ulcerative colitis market. This is due to men being more likely affected than women.
Disease type: Among the Disease type, Total colitis is expected to account for significant ulcerative colitis market share. However, Proctitis is expected to be the fastest-growing segment during the forecast period.
The portfolio contains a total of 106+ assets in various development phases. Most industry-sponsored drugs in active clinical development for ulcerative colitis are in the Phase II stage.
Segmentation by Geography
- North America
o US
- Europe
o France
o Germany
o Italy
o UK
o Spain
- APAC
o China
o Japan
ULCERATIVE COLITIS THERAPEUTICS: CLINICAL TRIALS SCENARIO
The clinical trial portfolio contains 155+ trials in various development phases. Most industry-sponsored drugs in active clinical development for inflammatory bowel disease are in Phase II, with three drugs in the NDA/BLA stage. The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for ulcerative colitis have been in the early and mid-phases of development, with 84% of trials in Phase I-II and only 16% in Phase III-IV. The US has a substantial lead in the number of ulcerative colitis clinical trials globally.
COMPETITIVE SCENARIO
The Ulcerative Colitis market is dominated by companies offering generic drugs and selective pharma/biotech companies offering patented/commercial drugs for treating UC. The US Food and Drug Administration (FDA) approved the TNF-Alpha agent Humira (Adalimumab) for treating ulcerative colitis in 2012. This marked the arrival of biologics in this treatment landscape. Following this, the FDA approved Jyseleca (filgotinib) and Rinvoq (upadacitinib) in 2022 and Zeposia (ozanimod) in 2021 for the treatment of UC. Although generic products continue to capture significant market share, the arrival of biologics and other targeted therapies indicates a paradigm shift in this therapeutic space through the forecast period.
The inflammatory bowel disease therapeutics portfolio contains a total of 106+ assets in various development phases. Some late-stage emerging inflammatory bowel disease Therapeutics include AJM-300, ontamalimab, CT-P13 SC, SHR-0302, mirikizumab, and others. Launching these novel emerging drugs will shift the inflammatory bowel disease treatment paradigm shortly. With more than 106 molecules in various stages of development, it is expected that new vendors are likely to enter the market with novel mechanisms of action and better safety and efficacy profiles compared to the existing patented commercial drugs for treating ulcerative colitis. Key vendors are likely to face stiff competition from emerging players whose drugs are in various stages of development for UC. Existing vendors need to compete with more than 90 vendors post the approval of their investigational molecules for inflammatory bowel disease treatment in the coming years.
The prominent players offering drugs in the market include Takeda, Abbvie, Janssen Pharmaceuticals, Pfizer, Bristol-Myers-Squibb, EA Pharma Co Ltd, Celltrion, ReiStone Biopharma, Eli Lilly and Company, and Index Pharmaceuticals. These players are focused on R&D initiatives to develop technologically advanced and innovative inflammatory bowel disease treatment drugs and are also entering into collaborations to maintain their market position.
Key Vendors
- Johnson & Johnson
- AbbVie Inc (AbbVie)
- Takeda Pharmaceutical Co Ltd (Takeda)
- Pfizer Inc (Pfizer)
- Bristol-Myers Squibb
- EA Pharma
- Eli Lilly and Company
- InDex
- Reistone Biopharma Co. Ltd.
- CellTrion
REPORT COVERAGE
- Detailed overview of ulcerative colitis, including disease definition, classification, diagnosis, and treatment pattern
- Overview of the global ulcerative colitis market trend in the eight major markets.
- Historical, current, and projected patient pool of ulcerative colitis in the eight major markets (8MM) for the 2018 2027 period
- Gender type, Disease type, Drug Class, and Geography type segmentation of the ulcerative colitis in the eight major markets (8MM)
- Historical, current, and projected market size of inflammatory bowel disease treatment market in the eight major markets (8MM) for the 2018 2027 period
- In-depth analysis of the market segments, which includes products, treatment, and competitor analysis
- Market share of the market players, company profiles, product specifications, and competitive landscape
- Comprehensive data on emerging trends, market drivers, growth opportunities, and restraints
- Detailed overview of marketed drugs with key coverage of developmental activities, including sponsor name, approved indication, territory, collaborations, licensing, mergers and acquisitions, regulatory designations, and other product-related activities
- Detailed overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for ulcerative colitis across the complete product development cycle, including all clinical and non-clinical stages
- Detailed overview of clinical trial activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and Geography type for ulcerative colitis across all clinical stages
- Coverage of dormant and discontinued pipeline projects and the reasons for ulcerative colitis.
- Coverage of major milestones (product approvals/launches timelines, clinical trial result publications, regulatory designations, licensing & collaborations, research & development progress of pipeline assets) in the ulcerative colitis space.
KEY QUESTIONS ANSWERED
1. HOW BIG IS THE GLOBAL ULCERATIVE COLITIS MARKET?
2. WHAT IS THE GROWTH RATE OF THE GLOBAL ULCERATIVE COLITIS MARKET?
3. WHO ARE THE KEY PLAYERS IN THE ULCERATIVE COLITIS (UC) MARKET?
4. WHAT ARE THE GROWTH FACTORS IN THE ULCERATIVE COLITIS MARKET?
CHAPTER - 1: ULCERATIVE COLITIS OVERVIEW
- Ulcerative Colitis - An Overview
CHAPTER - 2: ULCERATIVE COLITIS EPIDEMIOLOGY & OVERVIEW
- 8MM: Historic & Projected Volume of Incidence & Prevalence of Ulcerative Colitis
- 8MM: Comparative Analysis of Incidence & Prevalence of Ulcerative Colitis
- 8MM: Historic & Projected Volume of incidence of Ulcerative Colitis cases by Disease Type
- 8MM: Historic & Projected Volume of incidence of Ulcerative Colitis cases by Severity Type
- 8MM: Historic & Projected Volume of Incidence of Ulcerative Colitis cases by Gender & Age Group
- 8MM: Historic & Projected Volume of Prevalence of Ulcerative Colitis cases by Disease type
- 8MM: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Severity Type
- 8MM: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Gender & Age Group
- US: Historic & Projected Volume of Incidence & Prevalence of Ulcerative Colitis
- US: Comparative Analysis of Incidence & Prevalence of Ulcerative Colitis
- US: Historic & Projected Volume of incidence of Ulcerative Colitis Cases by Disease Type
- US: Historic & Projected Volume of incidence of Ulcerative Colitis Cases by Severity Type
- US: Historic & Projected Volume of Incidence of Ulcerative Colitis Cases by Gender & Age Group
- US: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Disease Type
- US: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Severity Type
- US: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Gender & Age Group
- China: Historic & Projected Volume of Incidence & Prevalence of Ulcerative Colitis
- China: Comparative Analysis of Incidence & Prevalence of Ulcerative Colitis
- China: Historic & Projected Volume of incidence of Ulcerative Colitis Cases by Disease Type
- China: Historic & Projected Volume of incidence of Ulcerative Colitis Cases by Severity Type
- China: Historic & Projected Volume of Incidence of Ulcerative Colitis Cases by Gender & Age Group
- China: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Disease Type
- China: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Severity Type
- China: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Gender & Age Group
- Japan: Historic & Projected Volume of Incidence & Prevalence of Ulcerative Colitis
- Japan: Comparative Analysis of Incidence & Prevalence of Ulcerative Colitis
- Japan: Historic & Projected Volume of incidence of Ulcerative Colitis Cases by Disease Type
- Japan: Historic & Projected Volume of incidence of Ulcerative Colitis Cases by Severity Type
- Japan: Historic & Projected Volume of Incidence of Ulcerative Colitis Cases by Gender & Age Group
- Japan: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Disease Type
- Japan: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Severity Type
- Japan: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Gender & Age Group
- Germany: Historic & Projected Volume of Incidence & Prevalence of Ulcerative Colitis
- Germany: Comparative Analysis of Incidence & Prevalence of Ulcerative Colitis
- Germany: Historic & Projected Volume of incidence of Ulcerative Colitis Cases by Disease Type
- Germany: Historic & Projected Volume of incidence of Ulcerative Colitis Cases by Severity Type
- Germany: Historic & Projected Volume of Incidence of Ulcerative Colitis Cases by Gender & Age Group
- Germany: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Disease Type
- Germany: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Severity Type
- Germany: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Gender & Age Group
- UK: Historic & Projected Volume of Incidence & Prevalence of Ulcerative Colitis
- UK: Comparative Analysis of Incidence & Prevalence of Ulcerative Colitis
- UK: Historic & Projected Volume of incidence of Ulcerative Colitis Cases by Disease Type
- UK: Historic & Projected Volume of incidence of Ulcerative Colitis Cases by Severity Type
- UK: Historic & Projected Volume of Incidence of Ulcerative Colitis Cases by Gender & Age Group
- UK: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Disease Type
- UK: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Severity Type
- UK: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Gender & Age Group
- France: Historic & Projected Volume of Incidence & Prevalence of Ulcerative Colitis
- France: Comparative Analysis of Incidence & Prevalence of Ulcerative Colitis
- France: Historic & Projected Volume of incidence of Ulcerative Colitis Cases by Disease Type
- France: Historic & Projected Volume of incidence of Ulcerative colitis cases by Severity Type
- France: Historic & Projected Volume of Incidence of Ulcerative Colitis Cases by Gender & Age Group
- France: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Disease Type
- France: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Severity Type
- France: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Gender & Age Group
- Italy: Historic & Projected Volume of Incidence & Prevalence of Ulcerative Colitis
- Italy: Comparative Analysis of Incidence & Prevalence of Ulcerative Colitis
- Italy: Historic & Projected Volume of incidence of Ulcerative Colitis Cases by Disease Type
- Italy: Historic & Projected Volume of incidence of Ulcerative Colitis Cases by Severity Type
- Italy: Historic & Projected Volume of Incidence of Ulcerative Colitis Cases by Gender & Age Group
- Italy: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Disease Type
- Italy: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Severity Type
- Italy: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Gender & Age Group
- Spain: Historic & Projected Volume of Incidence & Prevalence of Ulcerative Colitis
- Spain: Comparative Analysis of Incidence & Prevalence of Ulcerative Colitis
- Spain: Historic & Projected Volume of incidence of Ulcerative Colitis Cases by Disease Type
- Spain: Historic & Projected Volume of incidence of Ulcerative Colitis Cases by Severity Type
- Spain: Historic & Projected Volume of Incidence of Ulcerative Colitis Cases by Gender & Age Group
- Spain: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Disease Type
- Spain: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Severity Type
- Spain: Historic & Projected Volume of Prevalence of Ulcerative Colitis Cases by Gender & Age Group
CHAPTER - 3: ULCERATIVE COLITIS MARKET SIZE & OVERVIEW
- 8MM: Historic & Projected Revenue of Ulcerative Colitis
- 8MM: Historic & Projected Revenue of Ulcerative Colitis Snapshot
- 8MM: Major Approved Drugs in Ulcerative Colitis
- 8MM: Historic & Projected Revenue Segmentation by Gender Type, Disease Type & Drug Class
- US: Historic & Projected Revenue of Ulcerative Colitis
- US: Historic & Projected Revenue of Ulcerative Colitis Snapshot
- US: Historic & Projected Revenue Segmentation by Gender Type, Disease Type & Drug Class
- China: Historic & Projected Revenue of Ulcerative Colitis
- China: Historic & Projected Revenue of Ulcerative Colitis Snapshot
- China: Historic & Projected Revenue Segmentation by Gender Type, Disease Type,& Drug Class
- Japan: Historic & Projected Revenue of Ulcerative Colitis
- Japan: Historic & Projected Revenue of Ulcerative Colitis Snapshot
- Japan: Historic & Projected Revenue Segmentation by Gender Type, Disease Type & Drug Class
- Germany: Historic & Projected Revenue of Ulcerative Colitis
- Germany: Historic & Projected Revenue of Ulcerative Colitis Snapshot
- Germany: Historic & Projected Revenue Segmentation by Gender Type, Disease Type & Drug Class
- UK: Historic & Projected Revenue of Ulcerative Colitis
- UK: Historic & Projected Revenue of Ulcerative Colitis Snapshot
- UK: Historic & Projected Revenue Segmentation by Gender Type, Disease Type & Drug Class
- France: Historic & Projected Revenue of Ulcerative Colitis
- France: Historic & Projected Revenue of Ulcerative Colitis Snapshot
- France: Historic & Projected Revenue Segmentation by Gender Type, Disease Type & Drug Class
- Italy: Historic & Projected Revenue of Ulcerative Colitis
- Italy: Historic & Projected Revenue of Ulcerative Colitis Snapshot
- Italy: Historic & Projected Revenue Segmentation by Gender Type, Disease Type & Drug Class
- Spain: Historic & Projected Revenue of Ulcerative Colitis
- Spain: Historic & Projected Revenue of Ulcerative Colitis Snapshot
- Spain: Historic & Projected Revenue Segmentation by Gender Type, Disease Type & Drug Class
CHAPTER - 4: ULCERATIVE COLITIS MARKETED DRUGS OVERVIEW
- Ulcerative Colitis Marketed Drugs - An Overview
- Ulcerative Colitis Marketed Drugs - Summary
CHAPTER - 5: ULCERATIVE COLITIS PIPELINE DRUGS OVERVIEW
- Ulcerative Colitis Pipeline Drugs - An Overview
- Ulcerative Colitis Pipeline Drugs - Snapshot
- Ulcerative Colitis Pipeline Drugs Overview & Snapshot - By Disease type
- Ulcerative Colitis Pipeline Drugs Overview & Snapshot - By Development Phase
- Ulcerative Colitis Pipeline Drugs Overview & Snapshot - By Route of Administration
- Ulcerative Colitis Pipeline Drugs Overview & Snapshot - By Mechanism of Action
- Ulcerative Colitis Pipeline Drugs Overview & Snapshot - By Molecule type
- Ulcerative Colitis Pipeline Drugs Overview & Snapshot - By Geography type
CHAPTER - 6: ULCERATIVE COLITIS CLINICAL TRIALS OVERVIEW
- Ulcerative Colitis Clinical Trials Overview Snapshot
- Ulcerative Colitis Clinical Trials Overview - By Recruitment Status
- Ulcerative Colitis Clinical Trials Overview - By Product type
- Ulcerative Colitis Clinical Trials Overview - By Route of Administration
- Ulcerative Colitis Clinical Trials Overview - By Molecule type
- Ulcerative Colitis Clinical Trials Overview - By Geography type
CHAPTER - 7: ULCERATIVE COLITIS MARKET DYNAMICS
- Ulcerative Colitis Therapeutics Market Drivers
- Ulcerative Colitis Therapeutics Market Constraints
- Ulcerative Colitis Therapeutics Market Trends
CHAPTER - 8: ULCERATIVE COLITIS COMPETITIVE LANDSCAPE
- Ulcerative Colitis Competitive Landscape - Marketed Drugs
- Key Company Profiles
- Competitive Scenario of Ulcerative colitis therapeutics market
- Key Company Snapshot
- Ulcerative Colitis Competitive Landscape - Pipeline Drugs
- Key Emerging Company Profiles
- Key Company Snapshot
CHAPTER - 9: ULCERATIVE COLITIS MISCELLANEOUS
- Key Tentative Drug Approvals Timeline
- Key Regulatory Designations
- Key Milestones
- Deals & Collaborations
- Inactive/Discontinued/Dormant Products
CHAPTER - 10: APPENDIX
- About Arizton
- Research Methodology
- List of Abbreviations
LIST OF EXHIBITS
Exhibit 1: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN 8 MAJOR MARKETS (2018 - 2027)
Exhibit 2: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN 8 MAJOR MARKETS (2018 - 2020)
Exhibit 3: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN 8 MAJOR MARKETS (2021 - 2027)
Exhibit 4: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN 8 MAJOR MARKETS (2018 - 2027)
Exhibit 5: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN 8 MAJOR MARKETS (2018 - 2027)
Exhibit 6: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY AGE GROUP IN 8 MAJOR MARKETS (2018 - 2027)
Exhibit 7: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN 8 MAJOR MARKETS (2018 - 2027)
Exhibit 8: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN 8 MAJOR MARKETS (2018 - 2027)
Exhibit 9: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN 8 MAJOR MARKETS (2018 - 2027)
Exhibit 10: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY AGE GROUP IN 8 MAJOR MARKETS (2018 - 2027)
Exhibit 11: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN 8 MAJOR MARKETS (2018 - 2027)
Exhibit 12: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN US (2018 - 2027)
Exhibit 13: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN US (2018 - 2020)
Exhibit 14: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN US (2021 - 2027)
Exhibit 15: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN US (2018 - 2027)
Exhibit 16: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN US (2018 - 2027)
Exhibit 17: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY AGE GROUP IN US (2018 - 2027)
Exhibit 18: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN US (2018 - 2027)
Exhibit 19: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN US (2018 - 2027)
Exhibit 20: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN US (2018 - 2027)
Exhibit 21: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY AGE GROUP IN US (2018 - 2027)
Exhibit 22: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN US (2018 - 2027)
Exhibit 23: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN CHINA (2018 - 2027)
Exhibit 24: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN CHINA (2018 - 2020)
Exhibit 25: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN CHINA (2021 - 2027)
Exhibit 26: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN CHINA (2018 - 2027)
Exhibit 27: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN CHINA (2018 - 2027)
Exhibit 28: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY AGE GROUP IN CHINA (2018 - 2027)
Exhibit 29: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN CHINA (2018 - 2027)
Exhibit 30: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN CHINA (2018 - 2027)
Exhibit 31: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN CHINA (2018 - 2027)
Exhibit 32: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY AGE GROUP IN CHINA (2018 - 2027)
Exhibit 33: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN CHINA (2018 - 2027)
Exhibit 34: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN JAPAN (2018 - 2027)
Exhibit 35: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN JAPAN (2018 - 2020)
Exhibit 36: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN JAPAN (2021 - 2027)
Exhibit 37: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN JAPAN (2018 - 2027)
Exhibit 38: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN JAPAN (2018 - 2027)
Exhibit 39: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY AGE GROUP IN JAPAN (2018 - 2027)
Exhibit 40: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN JAPAN (2018 - 2027)
Exhibit 41: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN JAPAN (2018 - 2027)
Exhibit 42: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN JAPAN (2018 - 2027)
Exhibit 43: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY AGE GROUP IN JAPAN (2018 - 2027)
Exhibit 44: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN JAPAN (2018 - 2027)
Exhibit 45: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN GERMANY (2018 - 2027)
Exhibit 46: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN GERMANY (2018 - 2020)
Exhibit 47: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN GERMANY (2021 - 2027)
Exhibit 48: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN GERMANY (2018 - 2027)
Exhibit 49: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN GERMANY (2018 - 2027)
Exhibit 50: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY AGE GROUP IN GERMANY (2018 - 2027)
Exhibit 51: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN GERMANY (2018 - 2027)
Exhibit 52: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN GERMANY (2018 - 2027)
Exhibit 53: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN GERMANY (2018 - 2027)
Exhibit 54: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY AGE GROUP IN GERMANY (2018 - 2027)
Exhibit 55: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN GERMANY (2018 - 2027)
Exhibit 56: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN UK (2018 - 2027)
Exhibit 57: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN UK (2018 - 2020)
Exhibit 58: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN UK (2021 - 2027)
Exhibit 59: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN UK (2018 - 2027)
Exhibit 60: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN UK (2018 - 2027)
Exhibit 61: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY AGE GROUP IN UK (2018 - 2027)
Exhibit 62: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN UK (2018 - 2027)
Exhibit 63: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN UK (2018 - 2027)
Exhibit 64: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN UK (2018 - 2027)
Exhibit 65: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY AGE GROUP IN UK (2018 - 2027)
Exhibit 66: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN UK (2018 - 2027)
Exhibit 67: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN FRANCE (2018 - 2027)
Exhibit 68: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN FRANCE (2018 - 2020)
Exhibit 69: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN FRANCE (2021 - 2027)
Exhibit 70: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN FRANCE (2018 - 2027)
Exhibit 71: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN FRANCE (2018 - 2027)
Exhibit 72: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY AGE GROUP IN FRANCE (2018 - 2027)
Exhibit 73: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN FRANCE (2018 - 2027)
Exhibit 74: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN FRANCE (2018 - 2027)
Exhibit 75: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN FRANCE (2018 - 2027)
Exhibit 76: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY AGE GROUP IN FRANCE (2018 - 2027)
Exhibit 77: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN FRANCE (2018 - 2027)
Exhibit 78: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN ITALY (2018 - 2027)
Exhibit 79: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN ITALY (2018 - 2020)
Exhibit 80: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN ITALY (2021 - 2027)
Exhibit 81: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN ITALY (2018 - 2027)
Exhibit 82: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN ITALY (2018 - 2027)
Exhibit 83: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY AGE GROUP IN ITALY (2018 - 2027)
Exhibit 84: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN ITALY (2018 - 2027)
Exhibit 85: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN ITALY (2018 - 2027)
Exhibit 86: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN ITALY (2018 - 2027)
Exhibit 87: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY AGE GROUP IN ITALY (2018 - 2027)
Exhibit 88: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN ITALY (2018 - 2027)
Exhibit 89: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN SPAIN (2018 - 2027)
Exhibit 90: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN SPAIN (2018 - 2020)
Exhibit 91: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ULCERATIVE COLITIS IN SPAIN (2021 - 2027)
Exhibit 92: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN SPAIN (2018 - 2027)
Exhibit 93: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN SPAIN (2018 - 2027)
Exhibit 94: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY AGE GROUP IN SPAIN (2018 - 2027)
Exhibit 95: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN SPAIN (2018 - 2027)
Exhibit 96: HISTORIC & PROJECTED VOLUME OF PREVELANCE OF ULCERATIVE COLITIS BY DISEASE TYPE IN SPAIN (2018 - 2027)
Exhibit 97: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY SEVERITY TYPE IN SPAIN (2018 - 2027)
Exhibit 98: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY AGE GROUP IN SPAIN (2018 - 2027)
Exhibit 99: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ULCERATIVE COLITIS BY GENDER TYPE IN SPAIN (2018 - 2027)
Exhibit 100: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET IN 8 MAJOR MARKETS (2021 - 2027)
Exhibit 101: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET SNAPSHOT IN 8 MAJOR MARKETS (2018 - 2020)
Exhibit 102: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DISEASE TYPE IN 8 MAJOR MARKETS (2021 - 2027)
Exhibit 103: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY GENDER TYPE IN 8 MAJOR MARKETS (2021 - 2027)
Exhibit 104: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DRUG CLASS IN 8 MAJOR MARKETS (2021 - 2027)
Exhibit 105: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET IN US (2021 - 2027)
Exhibit 106: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET SNAPSHOT IN US (2018 - 2020)
Exhibit 107: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DISEASE TYPE IN US (2021 - 2027)
Exhibit 108: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY GENDER TYPE IN US (2021 - 2027)
Exhibit 109: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DRUG CLASS IN US (2021 - 2027)
Exhibit 110: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET IN CHINA (2021 - 2027)
Exhibit 111: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET SNAPSHOT IN CHINA (2018 - 2020)
Exhibit 112: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DISEASE TYPE IN CHINA (2021 - 2027)
Exhibit 113: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY GENDER TYPE IN CHINA (2021 - 2027)
Exhibit 114: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DRUG CLASS IN CHINA (2021 - 2027)
Exhibit 115: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET IN GERMANY (2021 - 2027)
Exhibit 116: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET SNAPSHOT IN GERMANY (2018 - 2020)
Exhibit 117: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DISEASE TYPE IN GERMANY (2021 - 2027)
Exhibit 118: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY GENDER TYPE IN GERMANY (2021 - 2027)
Exhibit 119: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DRUG CLASS IN GERMANY (2021 - 2027)
Exhibit 120: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET IN JAPAN (2021 - 2027)
Exhibit 121: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET SNAPSHOT IN JAPAN (2018 - 2020)
Exhibit 122: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DISEASE TYPE IN JAPAN (2021 - 2027)
Exhibit 123: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY GENDER TYPE IN JAPAN (2021 - 2027)
Exhibit 124: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DRUG CLASS IN JAPAN (2021 - 2027)
Exhibit 125: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET IN FRANCE (2021 - 2027)
Exhibit 126: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET SNAPSHOT IN FRANCE (2018 - 2020)
Exhibit 127: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DISEASE TYPE IN FRANCE (2021 - 2027)
Exhibit 128: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY GENDER TYPE IN FRANCE (2021 - 2027)
Exhibit 129: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DRUG CLASS IN FRANCE (2021 - 2027)
Exhibit 130: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET IN ITALY (2021 - 2027)
Exhibit 131: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET SNAPSHOT IN ITALY (2018 - 2020)
Exhibit 132: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DISEASE TYPE IN ITALY (2021 - 2027)
Exhibit 133: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY GENDER TYPE IN ITALY (2021 - 2027)
Exhibit 134: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DRUG CLASS IN ITALY (2021 - 2027)
Exhibit 135: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET IN UK (2021 - 2027)
Exhibit 136: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET SNAPSHOT IN UK (2018 - 2020)
Exhibit 137: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DISEASE TYPE IN UK (2021 - 2027)
Exhibit 138: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY GENDER TYPE IN UK (2021 - 2027)
Exhibit 139: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DRUG CLASS IN UK (2021 - 2027)
Exhibit 140: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET IN SPAIN (2021 - 2027)
Exhibit 141: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET SNAPSHOT IN SPAIN (2018 - 2020)
Exhibit 142: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DISEASE TYPE IN SPAIN (2021 - 2027)
Exhibit 143: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY GENDER TYPE IN SPAIN (2021 - 2027)
Exhibit 144: HISTORIC & PROJECTED REVENUE OF ULCERATIVE COLITIS THERAPEUTICS MARKET BY DRUG CLASS IN SPAIN (2021 - 2027)
Exhibit 145: MARKETED DRUGS OVERVIEW IN ULCERATIVE COLITIS THERAPEUTICS MARKET
Exhibit 146: MARKETED DRUGS OVERVIEW SNAPSHOT IN ULCERATIVE COLITIS THERAPEUTICS MARKET
Exhibit 147: PIPELINE DRUGS OVERVIEW IN ULCERATIVE COLITIS THERAPEUTICS MARKET
Exhibit 148: ULCERATIVE COLITIS PIPELINE DRUGS OVERVIEW BY DISEASE TYPE
Exhibit 149: ULCERATIVE COLITIS PIPELINE DRUGS OVERVIEW BY DEVELOPMENT PHASE
Exhibit 150: ULCERATIVE COLITIS PIPELINE DRUGS OVERVIEW BY ROUTE OF ADMINISTRATION
Exhibit 151: ULCERATIVE COLITIS PIPELINE DRUGS OVERVIEW BY MECHANISM OF ACTION
Exhibit 152: ULCERATIVE COLITIS PIPELINE DRUGS OVERVIEW BY MOLECULE TYPE
Exhibit 153: ULCERATIVE COLITIS PIPELINE DRUGS OVERVIEW BY GEOGRAPHY TYPE
Exhibit 154: ULCERATIVE COLITIS CLINICAL TRIAL ANALYSIS SNAPSHOT
Exhibit 155: ULCERATIVE COLITIS CLINICAL TRIAL ANALYSIS SNAPSHOT BY RECRUITMENT STATUS
Exhibit 156: ULCERATIVE COLITIS CLINICAL TRIAL ANALYSIS SNAPSHOT BY PRODUCT TYPE
Exhibit 157: ULCERATIVE COLITIS CLINICAL TRIAL ANALYSIS SNAPSHOT BY ROUTE OF ADMINISTRATION
Exhibit 158: ULCERATIVE COLITIS CLINICAL TRIAL ANALYSIS SNAPSHOT BY MOLECULE TYPE
Exhibit 159: ULCERATIVE COLITIS CLINICAL TRIAL ANALYSIS SNAPSHOT BY GEOGRAPHY TYPE
Exhibit 160: COMPETITIVE ASSESSMENT OF ULCERATIVE COLITIS THERAPEUTICS MARKET
LIST OF TABLES
Table 1: KEY MARKET DRIVERS IN ULCERATIVE COLITIS THERAPEUTICS MARKET
Table 2: KEY MARKET CONSTRAINTS IN ULCERATIVE COLITIS THERAPEUTICS MARKET
Table 3: KEY MARKET TRENDS IN ULCERATIVE COLITIS THERAPEUTICS MARKET
Table 4: KEY TENTATIVE TIMELINE APPROVALS OF PIPELINE DRUHS IN ULCERATIVE COLITIS
Table 5: KEY REGULATORY DESIGNATIONS OF PIPELINE DRUHS IN ULCERATIVE COLITIS
Table 6: KEY MILESTONES IN ULCERATIVE COLITIS THERAPEUTICS MARKET
Table 7: KEY DEALS & COLLABORATIONS IN ULCERATIVE COLITIS THERAPEUTICS MARKET
Table 8: KEY INACTIVE/DISCONTINUED PRODUCTS IN ULCERATIVE COLITIS THERAPEUTICS MARKET
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security